Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.39 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | SHBG | P04278 | 2/20 | 0.35 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584464 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL6804898 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL6804861 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL6839236 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL4585242 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL6804088 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL6802156 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL4593287 | 1.00 | GPBAR1 (0.47) | GPBAR1NR1H4CYP1B1CYP19A1G6PD | |
| SCHEMBL11970319 | 0.85 | NR3C1 (0.53) | GPBAR1NR1H4G6PDSLC10A1NR3C1 | |
| SCHEMBL11970322 | 0.85 | NR3C1 (0.53) | GPBAR1NR1H4G6PDSLC10A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499338-A4 | 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | SCHWARTZ ARTHUR (US) | 2008-06-18 | — | — | EP | claimed |
| EP-1499338-A1 | 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | Schwartz, Arthur (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040034003-A1 | 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof | BIOVIE INC. | 2004-02-19 | — | — | US | claimed |
| US-20040019026-A1 | Compounds useful for treating hypertriglyceridemia | BIOVIE INC. | 2004-01-29 | — | — | US | claimed |
| WO-2003092722-A1 | 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | SCHWARTZ ARTHUR (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1351971-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | Aeson Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002028880-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | AESON THERAPEUTICS INC. (US) | 2002-04-11 | — | — | WO | claimed |
| US-20040034003-A1 | 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof | BIOVIE INC. | 2004-02-19 | — | — | US | disclosed |
| US-20040019026-A1 | Compounds useful for treating hypertriglyceridemia | BIOVIE INC. | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019026-A1 | Compounds useful for treating hypertriglyceridemia | PNLIP, LIPC, LIPA | GPBAR1 140/4885NR1H4 124/4885CYP1B1 1376/4885 |
| US-20040034003-A1 | 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof | HSD17B11, CYP17A1, NR5A1 | GPBAR1 149/4885NR1H4 50/4885CYP1B1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.